Kenneth B.  Lee, Jr. net worth and biography

Kenneth Lee, Jr. Biography and Net Worth

Director of Eyenovia
Mr. Lee has been a member of our Board of Directors since March 2018. Since January 2003, he has been a general partner of Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies. Previously he was president of Pappas Capital, LLC (formerly A. M. Pappas & Associates, LLC), following 29 years with Ernst & Young LLP, where he was most recently managing director of the firm’s health sciences corporate finance group. Mr. Lee currently serves on the board of directors of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Previously, he served on the boards of several private and public companies, including Abgenix, Inc. (NASDAQ: ABGX, acquired by Amgen Inc. (NASDAQ: AMGN)), CV Therapeutics, Inc. (NASDAQ: CVTX, acquired by Gilead Sciences, Inc. (NASDAQ: GILD)), Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH, acquired by Merck & Co., Inc. NYSE: MRK), Maxygen, Inc. (NASDAQ: MAXY, dissolved), OSI Pharmaceuticals, Inc. (NASDAQ: OSIP, acquired by Astellas Pharma Inc. (OTC: ALPMY)), Old API Wind-down Ltd. (f/k/a Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), which began voluntary bankruptcy proceedings in Canada and filed for Chapter 11 bankruptcy in the United States in August 2018). Mr. Lee received a B.A. from Lenoir-Rhyne College and an M.B.A. from the University of North Carolina at Chapel Hill.

What is Kenneth B. Lee, Jr.'s net worth?

The estimated net worth of Kenneth B. Lee, Jr. is at least $2,244.83 as of June 11th, 2021. Mr. Lee, Jr. owns 21,359 shares of Eyenovia stock worth more than $2,245 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Lee, Jr. may own. Learn More about Kenneth B. Lee, Jr.'s net worth.

How do I contact Kenneth B. Lee, Jr.?

The corporate mailing address for Mr. Lee, Jr. and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Kenneth B. Lee, Jr.'s contact information.

Has Kenneth B. Lee, Jr. been buying or selling shares of Eyenovia?

Kenneth B. Lee, Jr. has not been actively trading shares of Eyenovia during the last quarter. Most recently, on Monday, June 14th, Kenneth B. Lee, Jr. bought 2,000 shares of Eyenovia stock. The stock was acquired at an average cost of $5.47 per share, with a total value of $10,940.00. Following the completion of the transaction, the director now directly owns 21,359 shares of the company's stock, valued at $116,833.73. Learn More on Kenneth B. Lee, Jr.'s trading history.

Who are Eyenovia's active insiders?

Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.

Are insiders buying or selling shares of Eyenovia?

In the last twelve months, Eyenovia insiders bought shares 7 times. They purchased a total of 1,757,829 shares worth more than $1,225,659.84. The most recent insider tranaction occured on August, 28th when CEO Michael M Rowe bought 27,071 shares worth more than $14,076.92. Insiders at Eyenovia own 7.1% of the company. Learn More about insider trades at Eyenovia.

Information on this page was last updated on 8/28/2024.

Kenneth B. Lee, Jr. Insider Trading History at Eyenovia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2021Buy2,000$5.47$10,940.0021,359View SEC Filing Icon  
6/11/2021Buy2,000$5.38$10,760.0021,359View SEC Filing Icon  
See Full Table

Kenneth B. Lee, Jr. Buying and Selling Activity at Eyenovia

This chart shows Kenneth B Lee Jr's buying and selling at Eyenovia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eyenovia Company Overview

Eyenovia logo
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.11
Low: $0.09
High: $0.11

50 Day Range

MA: $0.46
Low: $0.09
High: $0.57

2 Week Range

Now: $0.11
Low: $0.08
High: $2.57

Volume

17,145,351 shs

Average Volume

1,819,626 shs

Market Capitalization

$6.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75